DK2820010T3 - Benzofuran-2-sulfonamid-derivativer som kemokinreceptormodulatorer - Google Patents
Benzofuran-2-sulfonamid-derivativer som kemokinreceptormodulatorer Download PDFInfo
- Publication number
- DK2820010T3 DK2820010T3 DK13711995.4T DK13711995T DK2820010T3 DK 2820010 T3 DK2820010 T3 DK 2820010T3 DK 13711995 T DK13711995 T DK 13711995T DK 2820010 T3 DK2820010 T3 DK 2820010T3
- Authority
- DK
- Denmark
- Prior art keywords
- mmol
- retinal
- compound
- etoac
- nmr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (5)
- 1. Forbindelse med følgende formel, hydraterne, solvaterne, krystalformerne, tautomererne eller et farmaceutisk acceptabelt salt deraf:
- 2. Farmaceutisk sammensætning, der som aktiv bestanddel omfatter en terapeutisk effektiv mængde af en forbindelse ifølge krav 1 og en farmaceutisk acceptabel adjuvans, diluenter eller bærer.
- 3. Farmaceutisk sammensætning ifølge krav 2 til anvendelse i en fremgangsmåde til behandling afen lidelse, der er forbundet med kemokinreceptormodulering, hvilken fremgangsmåde omfatter administration af den farmaceutiske sammensætning til et pattedyr, som har behov derfor, hvor den lidelse, der er forbundet med kemokinreceptormodulering, er valgt blandt inflammatoriske hudsygdomme og -tilstande og inflammatoriske øjensygdomme.
- 4. Farmaceutisk sammensætning til anvendelse ifølge krav 3, hvor de inflammatoriske hudsygdomme og -tilstande er valgt blandt rosacea, solskoldning, kronisk solskade, diskrete erytemer, psoriasis, atopisk dermatitis, menopauseforbundne hedeture, hedeture som følge af orkiektomi, fotoaldring, seboroisk dermatitis, akne, allergisk dermatitis, irriterende dermatitis, telangiektasi i ansigtet, rinofym, rød løgformet næse, aknelignende huderuptioner, brændende eller svidende fornemmelse i ansigtet, irriterede og blodskudte og vandige øjne, kutan hyperaktivitet med udvidelse af hudens blodkar, Lyells syndrom, Stevens-Johnson-syndrom, erythema multiforme minor, erythema multiforme major og andre inflammatoriske hudsygdomme, aktiniske keratoser, arsenikkeratoser, inflammatorisk og ikke-inflammatorisk akne, iktyoser og andre keratiniseringslidelser og hyperproliferative lidelser i huden, eksem, sårheling; og hvor de inflammatoriske øjensygdomme er valgt blandt uveitis, tørt øje, keratitis, allergisk øjensygdom og -tilstande, der påvirker den bageste del af øjet, valgfrit valgt blandt makulopatier og retinal degeneration, herunder ikke-eksudativ aldersrelateret makulær degeneration, eksudativ aldersrelateret makulær degeneration, koroidal neovaskularisering, diabetisk retinopati, akut makulær neuroretinopati, central serøs korioretinopati, cystoid makulær ødem og diabetisk makulær ødem; uveitis, retinitis og koroiditis, valgfrit valgt blandt akut multifokal placoid pigmentepiteliopati, Behcets sygdom, "birdshot"-retinokoroidopati, infektiøs (syfilis, lyme, tuberkulose, toksoplasmose) intermediær uveitis, multifokal koroiditis, multipelt forbigående hvid plet-syndrom, okulær sarkoidose, posterior scleritis, serpiginøs koroiditis, subretinal fibrose og uveitissyndrom, Vogt-Koyanagi-Harada-syndrom; vaskulære sygdomme/eksudative sygdomme, valgfrit valgt blandt retinal arteriel okklusiv sygdom, central retinal veneokklusion, dissemineret intravaskulær koagulopati, retinal grenveneokklusion, hypertensive fundus-ændringer, okulær iskæmisk syndrom, retinale arterielle mikroaneurysmer, Coats sygdom, parafoveal telangiektase, hemiretinal veneokklusion, papillophlebitis, central retinal arterieokklusion, retinal grenarterieokklusion, karotidarteriesygdom, matteret gren-angiitis ("frosted branch angiitis"), seglcelleretinopati og andre hæmoglobinopatier, angioide striber, familiær eksudativ vitreoretinopati og Eales sygdom; traumatiske/kirurgiske tilstande, valgfrit valgt blandt sympatisk oftalmi, retinal uveitissygdom, retinal løsrivelse, traume, tilstande forårsaget af laser, tilstande forårsaget af fotodynamisk terapi, fotokoagulation, hypoperfusion under kirurgi, strålingsretinopati og knoglemarvstransplantationsretinopati; proliferative lidelser, valgfrit valgt blandt proliferativ vitreal retinopati og epiretinale membraner og proliferativ diabetisk retinopati; infektiøse lidelser, valgfrit valgt blandt okulær histoplasmose, okulær toksokariase, formodet okulær histoplasmosesyndrom, endophthalmitis, toksoplasmose, retinale sygdomme, som er forbundet med HIV-infektion, koroidal sygdom, som er forbundet med HIV-infektion, uveitissygdom, som er forbundet med HIV-infektion, viral retinitis, akut retinalnekrose, progressiv ydre retinalnekrose, retinale svampesygdomme, okulær syfilis, okulær tuberkulose, diffus unilateral subakut neuroretinitis og myiase; genetiske lidelser, valgfrit valgt blandt retinitis pigmentosa, systemiske lidelser med forbundne retinale dystrofier, kongenital stationær natteblindhed, tapdystrofier, Stargardts sygdom og fundus flavimaculatus, Bests' sygdom, mønsterdystrofi i det retinale pigmenterede epitel, X-bundet retinoskise, Sorsbys fundus-dystrofi, benign koncentrisk makulopati, Biettis krystallinsk dystrofi og pseudoxanthoma elasticum; retinale tårer/huller, valgfrit valgt blandt retinal løsrivelse, makulært hul og retinal gianttåre ("giant retinal tear"); tumorer, valgfrit valgt blandt retinal sygdom, som er forbundet med tumorer, kongenital hypertrofi i det retinale pigmenterede epitel, posterior uveal melanom, koroidal hæmangiom, koroidal osteom, koroidal metastase, kombineret hamartom i retina og retinal pigmenteret epitel, retinoblastom, vasoproliferative tumorer i den okulære fundus, retinal astrocytom og intraokulære lymfoide tumorer; og forskellige andre sygdomme, der påvirker den bageste del af øjet, valgfrit valgt blandt punktformig indre koroidopati, akut posterior multifokal placoid pigmentepiteliopati, myopisk retinal degeneration og akut retinal pigmentepiteliitis.
- 5. Farmaceutisk sammensætning til anvendelse ifølge krav 3 eller krav 4, hvor pattedyret er et menneske.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261605300P | 2012-03-01 | 2012-03-01 | |
PCT/US2013/028607 WO2013130962A1 (en) | 2012-03-01 | 2013-03-01 | Benzofuran- 2 - sulfonamide derivatives as chemokine receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2820010T3 true DK2820010T3 (da) | 2018-08-06 |
Family
ID=47902352
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18156011.1T DK3345899T3 (da) | 2012-03-01 | 2013-03-01 | Benzofuran-2-sulfonamidderivater som kemokinreceptormodulatorer |
DK13711995.4T DK2820010T3 (da) | 2012-03-01 | 2013-03-01 | Benzofuran-2-sulfonamid-derivativer som kemokinreceptormodulatorer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18156011.1T DK3345899T3 (da) | 2012-03-01 | 2013-03-01 | Benzofuran-2-sulfonamidderivater som kemokinreceptormodulatorer |
Country Status (12)
Country | Link |
---|---|
US (4) | US8815915B2 (da) |
EP (2) | EP3345899B1 (da) |
AU (2) | AU2013225815B2 (da) |
CA (1) | CA2866078C (da) |
CY (1) | CY1120528T1 (da) |
DK (2) | DK3345899T3 (da) |
ES (2) | ES2683046T3 (da) |
HU (2) | HUE049728T2 (da) |
PL (2) | PL3345899T3 (da) |
PT (2) | PT2820010T (da) |
SI (1) | SI2820010T1 (da) |
WO (2) | WO2013130958A1 (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815915B2 (en) * | 2012-03-01 | 2014-08-26 | Allergan, Inc. | Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators |
EP2970239B1 (en) | 2013-03-12 | 2018-10-10 | Allergan, Inc. | Sulfonamide derivatives as chemokine receptor modulators |
WO2015084869A1 (en) * | 2013-12-02 | 2015-06-11 | Allergan, Inc. | Benzothiophene sulfonamides derivatives as chemokine receptor modulators |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ536504A (en) * | 2002-05-24 | 2008-04-30 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
US20070021466A1 (en) * | 2002-11-18 | 2007-01-25 | Solomon Ungashe | CCR2 inhibitors and methods of use thereof |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
US7393873B2 (en) | 2003-07-02 | 2008-07-01 | Merck & Co., Inc. | Arylsulfonamide derivatives |
DE602004004663T2 (de) * | 2003-08-08 | 2007-11-22 | Janssen Pharmaceutica N.V. | Verfahren zur herstellung von 2- (chinoxalin-5-ylsulfonylamino) -benzamid-verbindungen |
US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
GB0524786D0 (en) | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
AU2007275873B2 (en) | 2006-07-14 | 2012-06-14 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
CA2692761C (en) | 2007-07-12 | 2013-04-30 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation |
TWI440638B (zh) * | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
EP2955173B1 (en) * | 2010-12-16 | 2017-10-04 | Allergan, Inc. | 1,2-bis-sulfonamide derivatives as chemokine receptor modulators |
EP2651957B1 (en) * | 2010-12-16 | 2015-02-18 | Allergan, Inc. | Phosphorous derivatives as chemokine receptor modulators |
US8524745B2 (en) * | 2011-12-12 | 2013-09-03 | Allergan, Inc. | Benzisothiazol-3(1H)-one-5-sulfonyl derivatives as chemokine receptor modulators |
US8815915B2 (en) * | 2012-03-01 | 2014-08-26 | Allergan, Inc. | Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators |
EP2970239B1 (en) * | 2013-03-12 | 2018-10-10 | Allergan, Inc. | Sulfonamide derivatives as chemokine receptor modulators |
-
2013
- 2013-03-01 US US13/782,174 patent/US8815915B2/en active Active
- 2013-03-01 DK DK18156011.1T patent/DK3345899T3/da active
- 2013-03-01 SI SI201331119T patent/SI2820010T1/sl unknown
- 2013-03-01 WO PCT/US2013/028599 patent/WO2013130958A1/en active Application Filing
- 2013-03-01 PT PT13711995T patent/PT2820010T/pt unknown
- 2013-03-01 HU HUE18156011A patent/HUE049728T2/hu unknown
- 2013-03-01 ES ES13711995.4T patent/ES2683046T3/es active Active
- 2013-03-01 AU AU2013225815A patent/AU2013225815B2/en active Active
- 2013-03-01 WO PCT/US2013/028607 patent/WO2013130962A1/en active Application Filing
- 2013-03-01 DK DK13711995.4T patent/DK2820010T3/da active
- 2013-03-01 PL PL18156011T patent/PL3345899T3/pl unknown
- 2013-03-01 EP EP18156011.1A patent/EP3345899B1/en active Active
- 2013-03-01 EP EP13711995.4A patent/EP2820010B1/en active Active
- 2013-03-01 PL PL13711995T patent/PL2820010T3/pl unknown
- 2013-03-01 ES ES18156011T patent/ES2791534T3/es active Active
- 2013-03-01 HU HUE13711995A patent/HUE038700T2/hu unknown
- 2013-03-01 PT PT181560111T patent/PT3345899T/pt unknown
- 2013-03-01 CA CA2866078A patent/CA2866078C/en active Active
- 2013-03-01 US US13/782,159 patent/US8927544B2/en active Active
-
2014
- 2014-07-17 US US14/334,145 patent/US9416120B2/en active Active
-
2015
- 2015-01-05 US US14/589,681 patent/US9550746B2/en active Active
-
2018
- 2018-01-11 AU AU2018200226A patent/AU2018200226B2/en active Active
- 2018-08-07 CY CY20181100816T patent/CY1120528T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US8815915B2 (en) | 2014-08-26 |
CA2866078A1 (en) | 2013-09-06 |
AU2013225815A1 (en) | 2014-09-25 |
PL3345899T3 (pl) | 2020-07-27 |
PL2820010T3 (pl) | 2018-11-30 |
ES2791534T3 (es) | 2020-11-04 |
US20140329813A1 (en) | 2014-11-06 |
WO2013130958A1 (en) | 2013-09-06 |
PT3345899T (pt) | 2020-05-20 |
US8927544B2 (en) | 2015-01-06 |
EP2820010B1 (en) | 2018-05-09 |
US20130231338A1 (en) | 2013-09-05 |
WO2013130962A1 (en) | 2013-09-06 |
AU2018200226B2 (en) | 2019-09-19 |
PT2820010T (pt) | 2018-10-01 |
US20150218119A1 (en) | 2015-08-06 |
CY1120528T1 (el) | 2019-07-10 |
DK3345899T3 (da) | 2020-05-11 |
ES2683046T3 (es) | 2018-09-24 |
EP3345899A1 (en) | 2018-07-11 |
AU2013225815B2 (en) | 2017-10-12 |
EP3345899B1 (en) | 2020-02-19 |
HUE038700T2 (hu) | 2018-11-28 |
US9550746B2 (en) | 2017-01-24 |
US9416120B2 (en) | 2016-08-16 |
US20130231339A1 (en) | 2013-09-05 |
EP2820010A1 (en) | 2015-01-07 |
SI2820010T1 (sl) | 2018-11-30 |
CA2866078C (en) | 2018-01-02 |
AU2018200226A1 (en) | 2018-01-25 |
HUE049728T2 (hu) | 2020-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2651957B1 (en) | Phosphorous derivatives as chemokine receptor modulators | |
AU2018200226B2 (en) | Benzofuran-2-sulfonamide derivatives as chemokine receptor modulators | |
CA2859024C (en) | Benzisothiazol-3(1h)-one-5-sulfonyl derivatives as chemokine receptor modulators | |
EP2970239B1 (en) | Sulfonamide derivatives as chemokine receptor modulators | |
WO2015084869A1 (en) | Benzothiophene sulfonamides derivatives as chemokine receptor modulators |